Defibrotide in Children With High Risk Kawasaki Disease

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

February 24, 2021

Primary Completion Date

October 24, 2023

Study Completion Date

June 30, 2024

Conditions
Kawasaki Disease
Interventions
DRUG

Defibrotide

Defibrotide 6.25 mg/kg IV q6h up to 7 days

Trial Locations (3)

10032

Columbia University, New York

New York University, New York

10595-1524

Mitchell Cairo, Valhalla

Sponsors
All Listed Sponsors
collaborator

Johns Hopkins University

OTHER

collaborator

Columbia University

OTHER

collaborator

New York University

OTHER

lead

New York Medical College

OTHER

NCT04777422 - Defibrotide in Children With High Risk Kawasaki Disease | Biotech Hunter | Biotech Hunter